Regulus Therapeutics, Inc. Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights

Published: Feb 21, 2013

LA JOLLA, Calif., Feb. 20, 2013 -- /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported its financial results for the fourth quarter and year-ended December 31, 2012 and recent company highlights.

Back to news